$LNZA
LanzaTech Global, Inc. Stock $lnza

$lnza Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023009618 Filed on March 29, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$9.646M	$0.00	$0.00
YoY Change
Cost Of Revenue	$7.790M	$60.00K	$250.0K
YoY Change	14439.01%	-69.72%	-35.3%
Gross Profit	$1.860M	-$60.00K	-$250.0K
YoY Change	-3571.44%	-69.72%	-35.3%
Gross Profit Margin	19.28%
Selling, General & Admin	$16.84M	$2.330M	$6.240M
YoY Change	516.29%	211.25%	523.09%
% of Gross Profit	905.11%
Research & Development	$16.29M		$53.19M
YoY Change	31.75%
% of Gross Profit	875.59%
Depreciation & Amortization	$1.257M		$4.660M
YoY Change	18.7%
% of Gross Profit	67.58%
Operating Expenses	$33.12M	$2.330M	$6.240M
YoY Change	1112.47%	211.25%	523.09%
Operating Profit	-$32.52M	-$2.390M	-$6.490M
YoY Change	1067.64%	152.45%	367.64%
Interest Expense	$214.0K	$230.0K	$5.270M
YoY Change	-128.25%	-56.27%	267.36%
% of Operating Profit
Other Income/Expense, Net	-$30.18M	$0.00	$170.0K
YoY Change	115984.62%
Pretax Income	-$62.70M	-$2.160M	-$1.049M
YoY Change	1669.83%	413.32%	-2344.6%
Income Tax	$0.00	$250.0K	$309.3K
% Of Pretax Income
Net Earnings	-$63.31M	-$2.410M	-$1.358M
YoY Change	1687.1%	472.73%	-3006.39%
Net Earnings / Revenue	-656.35%
Basic Earnings Per Share	-$0.58		-$12.37
Diluted Earnings Per Share	-$0.58	-$0.13	-$0.07
COMMON SHARES
Basic Shares Outstanding	195.5M shares		9.302M shares
Diluted Shares Outstanding	116.5M shares		9.302M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$194.2M	$0.00	$0.00
YoY Change	2334034.62%	-100.0%	-100.0%
Cash & Equivalents	$145.1M	$6.671K
Short-Term Investments	$49.10M
Other Short-Term Assets	$18.69M	$11.16M	$200.0K
YoY Change	4977.57%	3205.48%	-40.75%
Inventory		$1.129M
Prepaid Expenses		$190.6K
Receivables	$27.70M
Other Receivables	$0.00
Total Short-Term Assets	$240.6M	$197.3K	$200.0K
YoY Change	63837.07%	-71.02%	-70.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.79M	$19.69M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$9.835M	$10.56M	$152.3M
YoY Change	-93.44%	-92.96%	1.53%
Other Assets	$300.0K	$750.0K	$0.00
YoY Change	181.19%	305.82%	-100.0%
Total Long-Term Assets	$67.31M	$152.3M	$152.3M
YoY Change	-55.16%	1.4%	1.4%
TOTAL ASSETS
Total Short-Term Assets	$240.6M	$197.3K	$200.0K
Total Long-Term Assets	$67.31M	$152.3M	$152.3M
Total Assets	$308.0M	$152.5M	$152.5M
YoY Change	104.63%	1.08%	1.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.52M	$2.495M	$3.900M
YoY Change	16835.65%	2816.97%	2783.34%
Accrued Expenses	$9.600M	$2.257M	$2.700M
YoY Change	275.57%	882.47%	1075.29%
Deferred Revenue	$3.042M	$3.101M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.08M	$6.873M	$6.900M
YoY Change	983.55%	814.78%	818.33%
LONG-TERM LIABILITIES
Long-Term Debt	$19.40M	$50.00M	$0.00
YoY Change
Other Long-Term Liabilities	$1.591M	$1.591M	$2.800M
YoY Change	-86.32%	-85.35%	-74.22%
Total Long-Term Liabilities	$20.99M	$51.59M	$2.800M
YoY Change	80.49%	375.06%	-74.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.08M	$6.873M	$6.900M
Total Long-Term Liabilities	$20.99M	$51.59M	$2.800M
Total Liabilities	$78.15M	$9.714M	$9.700M
YoY Change	428.9%	-16.34%	-16.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$761.1M	-$8.334M
YoY Change	5228.73%	-22.4%
Common Stock	$19.00K	$1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$229.8M	-$8.333M	$142.8M
YoY Change
Total Liabilities & Shareholders Equity	$308.0M	$152.5M	$152.5M
YoY Change	104.63%	1.08%	1.08%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$63.31M	-$2.410M	-$1.358M
YoY Change	1687.1%	472.73%	-3006.39%
Depreciation, Depletion And Amortization	$1.257M		$4.660M
YoY Change	18.7%
Cash From Operating Activities	-$33.81M	$0.00	-$345.7K
YoY Change	9726.09%	-100.0%	-32.21%
INVESTING ACTIVITIES
Capital Expenditures	$1.367M		$10.74M
YoY Change	-27.71%
Acquisitions
YoY Change
Other Investing Activities	-$109.2M	$0.00	$10.00K
YoY Change	-1213433.33%		-100.01%
Cash From Investing Activities	-$110.6M	$0.00	$9.000K
YoY Change	-1228611.11%		-100.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$206.5M		$50.55M
YoY Change			-66.49%
NET CHANGE
Cash From Operating Activities	-$33.81M	0.000	-$345.7K
Cash From Investing Activities	-$110.6M	0.000	$9.000K
Cash From Financing Activities	$206.5M		$50.55M
Net Change In Cash	$62.10M	0.000	-$336.7K
YoY Change	-18632.96%	-100.0%	-198.06%
FREE CASH FLOW
Cash From Operating Activities	-$33.81M	$0.00	-$345.7K
Capital Expenditures	$1.367M		$10.74M
Free Cash Flow	-$35.18M		-$11.08M
YoY Change	1473.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001843724
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	146550000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	195451598	shares
CY2022	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Location AuditorLocation	New York, NY
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6671	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	190645	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	337534	usd
CY2022Q4	amci	Prepaid Expenses Long Term PrepaidExpensesLongTerm	0	usd
CY2021Q4	amci	Prepaid Expenses Long Term PrepaidExpensesLongTerm	184812	usd
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	152296551	usd
CY2021Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	150006015	usd
CY2022Q4	us-gaap	Assets Assets	152493867	usd
CY2021Q4	us-gaap	Assets Assets	150871760	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2494997	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	85534	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2257059	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	229733	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1374000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	49723	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current And Noncurrent AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent	394311	usd
CY2021Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current And Noncurrent AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent	198129	usd
CY2022Q4	amci	Franchise Tax Payable Current FranchiseTaxPayableCurrent	43552	usd
CY2021Q4	amci	Franchise Tax Payable Current FranchiseTaxPayableCurrent	188237	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	309320	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent		usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6873239	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	751356	usd
CY2022Q4	amci	Deferred Underwriting Compensation Noncurrent DeferredUnderwritingCompensationNoncurrent	200000	usd
CY2021Q4	amci	Deferred Underwriting Compensation Noncurrent DeferredUnderwritingCompensationNoncurrent	5250000	usd
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	2640370	usd
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	5610000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9713609	usd
CY2021Q4	us-gaap	Liabilities Liabilities	11611356	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8333750	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10739971	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8333375	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10739596	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152493867	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	150871760	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5923760	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	951461	usd
CY2022	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	120000	usd
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	50000	usd
CY2022	amci	Capital Base Tax Expense CapitalBaseTaxExpense	246182	usd
	amci	Capital Base Tax Expense CapitalBaseTaxExpense	198129	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-150000000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	150000000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	852416	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150853416	usd
CY2022	us-gaap	Production Tax Expense ProductionTaxExpense	200050	usd
	us-gaap	Production Tax Expense ProductionTaxExpense	188237	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6489992	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1387827	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2969630	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1905000	usd
CY2022	amci	Gain Loss From Extinguishment Of Deferred Underwriting Commissions On Public Warrants GainLossFromExtinguishmentOfDeferredUnderwritingCommissionsOnPublicWarrants	171700	usd
CY2022	amci	Offering Costs Allocated To Derivative Warrant Liabilities OfferingCostsAllocatedToDerivativeWarrantLiabilities	0	usd
	amci	Offering Costs Allocated To Derivative Warrant Liabilities OfferingCostsAllocatedToDerivativeWarrantLiabilities	476450	usd
CY2022	amci	Income From Investments Held In Trust Account IncomeFromInvestmentsHeldInTrustAccount	2299536	usd
	amci	Income From Investments Held In Trust Account IncomeFromInvestmentsHeldInTrustAccount	6015	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1049126	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	309320	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1358446	usd
	us-gaap	Net Income Loss NetIncomeLoss	46738	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	0	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1085000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0	usd
	amci	Contribution From Sponsor Upon Sale Of Founder Shares To Anchor Investors ContributionFromSponsorUponSaleOfFounderSharesToAnchorInvestors	6509758	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-18406092	usd
	us-gaap	Net Income Loss NetIncomeLoss	46738	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10739596	usd
CY2022	amci	Adjustment To Additional Paid In Capital Extinguishment Of Deferred Underwriting Commissions On Public Shares AdjustmentToAdditionalPaidInCapitalExtinguishmentOfDeferredUnderwritingCommissionsOnPublicShares	4878300	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	0	usd
CY2022	amci	Increase Or Decrease In Equity Due To Re Measurement Of Common Stock Subject To Possible Redemption IncreaseOrDecreaseInEquityDueToReMeasurementOfCommonStockSubjectToPossibleRedemption	-1113633	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1358446	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8333375	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1358446	usd
	us-gaap	Profit Loss ProfitLoss	46738	usd
	amci	General And Administrative Expenses Paid By Sponsor In Exchange For Shares GeneralAndAdministrativeExpensesPaidBySponsorInExchangeForShares	1000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2969630	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1905000	usd
CY2022	amci	Gain Loss From Extinguishment Of Deferred Underwriting Commissions On Public Warrants GainLossFromExtinguishmentOfDeferredUnderwritingCommissionsOnPublicWarrants	171700	usd
	amci	Offering Costs Allocated To Derivative Warrant Liabilities OfferingCostsAllocatedToDerivativeWarrantLiabilities	476450	usd
CY2022	amci	Income From Investments Held In Trust Account IncomeFromInvestmentsHeldInTrustAccount	2299536	usd
	amci	Income From Investments Held In Trust Account IncomeFromInvestmentsHeldInTrustAccount	6015	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-331701	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-155454	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2409463	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	85534	usd
CY2022	amci	Increase Decrease In Due To Related Parties. IncreaseDecreaseInDueToRelatedParties.	1324277	usd
	amci	Increase Decrease In Due To Related Parties. IncreaseDecreaseInDueToRelatedParties.	49723	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2027326	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	199733	usd
CY2022	amci	Increase Decrease In Capital Base Tax Payable IncreaseDecreaseInCapitalBaseTaxPayable	196182	usd
	amci	Increase Decrease In Capital Base Tax Payable IncreaseDecreaseInCapitalBaseTaxPayable	198129	usd
CY2022	amci	Increase Decrease Franchise Tax Payable IncreaseDecreaseFranchiseTaxPayable	-144685	usd
	amci	Increase Decrease Franchise Tax Payable IncreaseDecreaseFranchiseTaxPayable	188237	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	309320	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-345728	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-510017	usd
	us-gaap	Payments To Acquire Trust Preferred Investments PaymentsToAcquireTrustPreferredInvestments	150000000	usd
CY2022	amci	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	-9000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-336728	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	343399	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	343399	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6671	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	343399	usd
	amci	Deferred Offering Costs Included In Notes Payable DeferredOfferingCostsIncludedInNotesPayable	1968784	usd
	amci	Offering Costs Included In Accounts Payable Accrued Expenses OfferingCostsIncludedInAccountsPayableAccruedExpenses	30000	usd
	amci	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	24000	usd
	amci	Noncash Prepaid Expenses And Other Assets Paid By Related Parties NoncashPrepaidExpensesAndOtherAssetsPaidByRelatedParties	677800	usd
	amci	Noncash Repayment Of Note Payable And Advances NoncashRepaymentOfNotePayableAndAdvances	2647584	usd
	amci	Noncash Deferred Underwriting Commissions NoncashDeferredUnderwritingCommissions	5250000	usd
	amci	Value Of Class B Common Stock Transferred To Anchor Investors At Initial Public Offering ValueOfClassBCommonStockTransferredToAnchorInvestorsAtInitialPublicOffering	6509758	usd
CY2022	amci	Noncash Extinguishment Of Deferred Underwriting Commissions On Public Shares NoncashExtinguishmentOfDeferredUnderwritingCommissionsOnPublicShares	4878300	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Description of Organization and Business Operations<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LanzaTech Global, Inc., formerly known as AMCI Acquisition Corp. II prior to February 8, 2023 (the “Closing Date”) (the “Company”), was a blank check company incorporated as a Delaware corporation on January 28, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> one or more businesses (the “business combination”). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combination</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, the Company consummated the previously announced business combination pursuant to the terms of the Agreement and Plan of Merger (the “Closing”), dated as of March 8, 2022 (as amended on December 7, 2022, the “Merger Agreement”), by and among AMCI, AMCI Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and LanzaTech NZ, Inc., a Delaware corporation (“Legacy LanzaTech”). Pursuant to the Merger Agreement, on the Closing Date, (i) AMCI changed its name to “LanzaTech Global, Inc.” (“New LanzaTech”), and (ii) Merger Sub merged with and into Legacy LanzaTech, with Legacy LanzaTech as the surviving company in the Business Combination. After giving effect to such Business Combination, Legacy LanzaTech became a wholly owned subsidiary of New LanzaTech. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, at the effective time of the Business Combination (the “Effective Time”), (i) each outstanding share of common stock of Legacy LanzaTech (the “Legacy LanzaTech common stock”) was converted into the right to receive 4.374677 shares of common stock, par value $0.0001 per share, of New LanzaTech (the “Common Stock”); (ii) each warrant to purchase Legacy LanzaTech common stock that was outstanding and unexercised immediately prior to the Effective Time and would automatically be exercised or exchanged in full in accordance with its terms by virtue of the occurrence of the Business Combination, was automatically exercised or exchanged in full for the applicable shares of Legacy LanzaTech capital stock, and each such share of Legacy LanzaTech capital stock was treated as being issued and outstanding immediately prior to the Effective Time and was cancelled and converted into the right to receive the applicable shares of Common Stock; (iii) each warrant to purchase Legacy LanzaTech common stock that was outstanding and unexercised prior to the Effective Time and was not automatically exercised in full as described in clause (ii) was converted into a warrant to purchase shares of Common Stock, in which case (a) the number of shares underlying such New LanzaTech warrant was determined by multiplying the number of shares of Legacy LanzaTech capital stock subject to such warrant immediately prior to the Effective Time, by 4.374677 and (b) the per share exercise price of such New LanzaTech warrant was determined by dividing the per share exercise price of such Legacy LanzaTech warrant immediately prior to the Effective Time by 4.374677, except that in the case of a certain warrant issued by Legacy LanzaTech to ArcelorMittal XCarb S.à r.l on December 8, 2021, such exercise price is $10.00; and (iv) to the extent not converted in full immediately prior to the Effective Time, the Brookfield SAFE was assumed by New LanzaTech and is convertible into 5,000,000 shares of Common Stock. In addition, the accumulated dividends payable to the holders of Legacy LanzaTech preferred shares in connection with the share conversion based on the applicable conversion ratio at the Effective Time were settled by delivery of Common Stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, at the Effective Time, each Legacy LanzaTech option was converted into New LanzaTech options to purchase a number of shares of Common Stock (rounded down to the nearest whole share) equal to the product of (i) the number of Legacy LanzaTech common shares subject to such Legacy LanzaTech option multiplied by (ii) 4.374677. The exercise price of such New LanzaTech options is equal to the quotient of (a) the exercise price per share of such Legacy LanzaTech option in effect immediately prior to the Effective Time divided by (b) 4.374677 (and as so determined, this exercise price will be rounded up to the nearest full cent). Pursuant to the Merger Agreement, at the Effective Time, each Legacy LanzaTech RSA that was outstanding immediately prior to the Effective Time was converted into a New LanzaTech RSA on the same terms and conditions as were applicable to such Legacy LanzaTech RSA immediately prior to the Effective Time, except that such New LanzaTech RSA will relate to a number of shares of Common Stock equal to the number of Legacy LanzaTech common shares subject to such Legacy LanzaTech RSA, multiplied by 4.374677.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Prior to the Business Combination</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company has neither engaged in any operations nor generated any revenues. All activity for the period from January 28, 2021 (inception) through December 31, 2022 relates to the Company’s formation and the initial public offering (“initial public offering”), described below. The Company will not generate any operating revenues until after the completion of its initial business combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the initial public offering and from changes in the fair value of its derivative warrant liabilities, if applicable. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s sponsor is AMCI Sponsor II LLC, a Delaware limited liability company (the “Sponsor”).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registration statement for the Company’s initial public offering was declared effective on August 3, 2021 (the “effective date”). On August 6, 2021, the Company consummated its initial public offering (the “initial public offering”) of 15,000,000 units (the “units”). Each unit consists of one Class A common stock of the Company, par value $0.0001 per share (the “Class A common stock”), and one-half of one redeemable warrant of the Company (the “warrant”), each whole warrant entitling the holder thereof to purchase one Class A common stock for $11.50 per share. The units were sold at a price of $10.00 per unit, generating gross proceeds to the Company of $150,000,000, which is discussed in Note 3.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously with the closing of the initial public offering, the Company completed the private sale of an aggregate of 3,500,000 warrants (the “private placement warrants”) to the Sponsor at a purchase price of $1.00 per private placement warrant, generating gross proceeds to the Company of $3,500,000. The private placement warrants are identical to the warrants sold in the initial public offering, except that the private placement warrants, so long as they are held by the Sponsor or its permitted transferees, (i) are not redeemable by the Company, (ii) may not (including the Class A common stock issuable upon exercise of such private placement warrants), subject to certain limited exceptions, be transferred, assigned or sold by such holders until 30 days after the completion of the Company’s initial business combination, (iii) may be exercised by the holders on a cashless basis and (iv) will be entitled to registration rights. No underwriting discounts or commissions were paid with respect to such sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the initial public offering includes two instruments, Class A common stock and warrants, and as the warrants are classified as a financial liability, it is necessary to allocate the gross proceeds between Class A common stock and warrants. The Company adopted the residual method to allocate the gross proceeds between Class A common stock and warrants based on their relative fair values. The gross proceeds were first allocated to the fair value of the warrants and the residual amount was allocated to the Class A common stock. The percentage derived from this allocation was used to allocate the deferred offering costs between Class A common stock and warrants. Issuance costs allocated to the warrants were expensed to the Company’s statement of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of the initial public offering amounted to $13,782,542 and consisted of $1,500,000 of underwriting discount, $5,250,000 of deferred underwriting discount, $6,509,758 in fair value of Class B common stock issued to Anchor Investors, and $522,784 of other offering costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of $150,000,000 was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee (the “trust account”).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of common stock subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the initial public offering, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a business combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a business combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the business combination.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with those of another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is continuing to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IR Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”), which, among other things, imposes a new 1% U.S. federal excise tax on certain repurchases of stock by “covered corporations” (which include publicly traded domestic (i.e., U.S.) corporations) beginning in 2023, with certain exceptions (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Excise Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”). The Excise Tax is imposed on the repurchasing corporation itself, not its stockholders from which the stock is repurchased. Because we are a Delaware corporation and our securities are trading on Nasdaq, we are a “covered corporation” for this purpose. The amount of the Excise Tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the Excise Tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the Excise Tax. The U.S. Department of the Treasury has authority to provide regulations and other guidance to carry out, and prevent the abuse or avoidance of the Excise Tax. It is uncertain whether, and/or to what extent, the Excise Tax could apply to any repurchase by us of our common stock or in the event of our liquidation, in each instance after December 31, 2022, including any redemptions in connection with an initial business combination or in the event we do not consummate an initial business combination by August 6, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had approximately $7,000 in its operating bank account and a working capital deficit of approximately $5.9 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s liquidity needs up to December 31, 2022 have been satisfied through a contribution of $25,000 from the Sponsor to cover for certain offering costs in exchange for the issuance of Founder Shares, and a loan and advances from the Sponsor pursuant to the Note (as defined in Note 4). Subsequent to the initial public offering, net </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the private placement of $0.9 million were placed in the operating account for working capital purposes. In addition, in order to finance transaction costs in connection with a business combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 4). On March 28, 2022, the Company entered into a noninterest-bearing Working Capital Loan with its Sponsor for the principal amount of up to $1.5 million. As of December 31, 2022 and 2021, there were no amounts outstanding under any Working Capital Loan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Merger Agreement, AMCI entered into subscription agreements (as amended on December 7, 2022, the “Initial Subscription Agreements”) with certain investors (the “Initial PIPE Investors”). AMCI entered into additional subscription agreements with certain institutional and accredited investors (the “PIPE Investors”) on October 8, 2022 (as amended on December 7, 2022) and February 6, 2022 (collectively, the “PIPE Subscription Agreements” and together with the subscription agreement between AMCI and ArcelorMittal, the “Subscription Agreements”). Pursuant to the Subscription Agreements, the PIPE Investors purchased an aggregate of 18,500,000 shares of common stock in a private placement at a price of $10.00 per share for an aggregate purchase price of $185 million (the “PIPE Investment”). Such aggregate number of shares and aggregate purchase price include 3,000,000 shares of common stock issued to ArcelorMittal pursuant to the AM SAFE with Legacy LanzaTech, as a result of which such PIPE Investor entered into a Subscription Agreement prior to the closing of the Business Combination. The PIPE Investment was consummated in connection with the consummation of the Business Combination. Upon closing of the Business Combination, the Company retained $153 million net of transaction expenses as working capital.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the Business Combination, the Company’s immediate sources of liquidity include cash generated from operations, accounts receivable, and existing credit facilities of LanzaTech. Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through one year from this filing.</span></div>
	amci	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1	item
CY2021Q3	amci	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	150000000	usd
CY2022Q4	amci	Condition For Future Business Combination Threshold Net Tangible Assets ConditionForFutureBusinessCombinationThresholdNetTangibleAssets	5000001	usd
CY2022Q4	amci	Proceeds Held In Operating Account For Working Capital Purpose ProceedsHeldInOperatingAccountForWorkingCapitalPurpose	7000	usd
	amci	Working Capital Deficit WorkingCapitalDeficit	5900000	usd
CY2022Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	18500000	shares
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.00
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	185000000	usd
CY2022Q4	amci	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	153000000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of December 31, 2022 and 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></div>
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is </span></div>at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1	shares
CY2022Q4	amci	Class Of Warrant Or Right Price Of Warrants Or Rights ClassOfWarrantOrRightPriceOfWarrantsOrRights	11.50
CY2022	amci	Warrants And Rights Outstanding Exercisable Term From Closing Of Initial Public Offering WarrantsAndRightsOutstandingExercisableTermFromClosingOfInitialPublicOffering	P30D
CY2022	amci	Maximum Threshold Period For Filing Registration Statement After Business Combination MaximumThresholdPeriodForFilingRegistrationStatementAfterBusinessCombination	P5Y
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1	shares
CY2021Q4	amci	Outstanding Working Capital Loans OutstandingWorkingCapitalLoans	0	usd
CY2022Q4	amci	Maximum Number Of Demands For Registration Of Securities MaximumNumberOfDemandsForRegistrationOfSecurities	3	item
CY2021Q3	amci	Number Of Shares Subject To Forfeiture NumberOfSharesSubjectToForfeiture	562500	shares
CY2021Q3	amci	Underwriting Discount Percentage UnderwritingDiscountPercentage	0.01
CY2021Q3	amci	Underwriter Cash Discount UnderwriterCashDiscount	1500000	usd
CY2021Q3	amci	Deferred Underwriting Discount Percentage DeferredUnderwritingDiscountPercentage	0.035
CY2021Q3	amci	Deferred Underwriting Discounts DeferredUnderwritingDiscounts	5250000	usd
CY2022	amci	Adjustment To Additional Paid In Capital Extinguishment Of Deferred Underwriting Commissions On Public Shares AdjustmentToAdditionalPaidInCapitalExtinguishmentOfDeferredUnderwritingCommissionsOnPublicShares	4900000	usd
CY2022Q4	amci	Deferred Underwriting Discounts DeferredUnderwritingDiscounts	172000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3000000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1900000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	309320	usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-15220	usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-290181	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15220	usd
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	290181	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	309320	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	amci	Deferred Tax Assets Capitalized Start Up And Organization Costs DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts	305401	usd
CY2021Q4	amci	Deferred Tax Assets Capitalized Start Up And Organization Costs DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts	210307	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	79874	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	305401	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	290181	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	305401	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	290181	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	305401	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	290181	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	amci	Effective Income Tax Rate Reconciliation Derivative Warrant Liabilities Change In Fair Value Percent EffectiveIncomeTaxRateReconciliationDerivativeWarrantLiabilitiesChangeInFairValuePercent	0.594
	amci	Effective Income Tax Rate Reconciliation Derivative Warrant Liabilities Change In Fair Value Percent EffectiveIncomeTaxRateReconciliationDerivativeWarrantLiabilitiesChangeInFairValuePercent	-8.559
CY2022	amci	Effective Income Tax Rate Reconciliation Derivative Warrant Liabilities Offering Costs Percent EffectiveIncomeTaxRateReconciliationDerivativeWarrantLiabilitiesOfferingCostsPercent	0.000
	amci	Effective Income Tax Rate Reconciliation Derivative Warrant Liabilities Offering Costs Percent EffectiveIncomeTaxRateReconciliationDerivativeWarrantLiabilitiesOfferingCostsPercent	2.140
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.034
	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	amci	Effective Income Tax Rate Reconciliation Capitalized Merger Costs EffectiveIncomeTaxRateReconciliationCapitalizedMergerCosts	-1.119
	amci	Effective Income Tax Rate Reconciliation Capitalized Merger Costs EffectiveIncomeTaxRateReconciliationCapitalizedMergerCosts	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.015
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	6.209
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.296
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000

Files In Submission

Name	View Source	Status
amci-20221231_lab.xml	Edgar Link	unprocessable
amci-20221231_cal.xml	Edgar Link	unprocessable
amci-20221231_pre.xml	Edgar Link	unprocessable
amci-20221231_def.xml	Edgar Link	unprocessable
0001628280-23-009618-index-headers.html	Edgar Link	pending
0001628280-23-009618-index.html	Edgar Link	pending
0001628280-23-009618.txt	Edgar Link	pending
0001628280-23-009618-xbrl.zip	Edgar Link	pending
amci-20221231.htm	Edgar Link	pending
amci-20221231.xsd	Edgar Link	pending
amci-20221231_g1.jpg	Edgar Link	pending
amci-20221231_g2.jpg	Edgar Link	pending
amci-20221231_g3.jpg	Edgar Link	pending
amci-20221231_g4.jpg	Edgar Link	pending
amci-20221231_g5.jpg	Edgar Link	pending
amci-20221231_g6.jpg	Edgar Link	pending
exhibit231-10xk.htm	Edgar Link	pending
exhibit311-10xk.htm	Edgar Link	pending
exhibit312-10xk.htm	Edgar Link	pending
exhibit321-10xk.htm	Edgar Link	pending
exhibit322-10xk.htm	Edgar Link	pending
exhibit991-10xk.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
amci-20221231_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LNZA
LanzaTech Global, Inc. Stock $lnza

2023 Q1 Form 10-K Financial Statement

#000162828023009618 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNZA LanzaTech Global, Inc. Stock $lnza

2023 Q1 Form 10-K Financial Statement

#000162828023009618 Filed on March 29, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LNZA
LanzaTech Global, Inc. Stock $lnza